Skip to Main Content
Services Talent Knowledge
Site Search


Our attorneys stay on top of changes in legislation, agency regulations, case law, and industry trends—then craft timely legal alerts to keep clients up to date on legal developments important to their business.

March 9, 2017

Governor Cuomo's Salvo to Combat Soaring Prescription Drug Prices

Drug manufacturers and pharmacy benefit managers continue to be fodder for politicians looking to make splashy headlines on the issue surrounding responsibility for soaring prescription drug prices. The issue is gripping the nation, and politicians from the President to governors are circling the wagons. New York Governor Andrew Cuomo is no exception.

On January 12, 2017, Governor Cuomo announced a new proposal aimed at curbing "skyrocketing costs of prescription drugs" in the Medicaid program. The broad scope of the proposed reform was justified by the impact drug costs are having on our New York Medicaid program, which has incurred a $1.7 billion drug-related cost increase over the past 3 years. More troubling is that 77% of Americans are foregoing medications because of cost, according to the Governor.

The Governor's initiative outlined a three-pronged approach that proposes to:

  • Protect taxpayers by preventing prescription drug price gouging in the Medicaid Program through the implementation of a price ceiling on "high cost prescription drugs" that will require a 100% rebate of amounts paid over a "benchmark" price to be set by the Drug Utilization Review Board.
  • Impose a surcharge on drug manufacturers that charge exorbitant prices on these "high cost prescription drugs" that will be placed in a dedicated fund to be reallocated to insurers to lower premiums for businesses the following year.
  • Protect consumers from abusive business practices by pharmacy benefit managers (PBMs) that drive up drug prices in an industry "rife with conflicts of interests and undisclosed arrangements entered into at the customers' expense." To bring an end to these practices, the Governor proposes:
    • Mandated disclosure of financial incentives, benefits for promoting the use of certain drugs or other financial arrangements affecting customers; and
    • Increased State oversight requiring PBMs to register with the State Department of Financial Services ("DFS"). DFS would have authority to suspend or revoke a PBM's license for deceptive, unfair, or abusive business practices or any other conduct that violates the standards set by the Department.

The Governor termed the proposal "ground-breaking" and although he called for an "immediate" stop to this "unconscionable" behavior, he is not seeking implementation of the regulations on PBMs, which are the teeth of the proposal, until 2019. Moreover, the proposal is only for unspecified "high cost prescription drugs" in the Medicaid program, which will leave many New Yorkers continuing to feel the effects of the increasing burden of drug costs both at the pharmacy counter and in the premiums paid for coverage.

Even if Governor Cuomo follows through and his proposal becomes law, a challenge by PBMs could lead to it being found pre-empted by the Employee Retirement Income Security Act of 1974 ("ERISA"), 29 U.S.C. §§ 1001, et seq. Indeed, less than one month ago, the U.S. Court of Appeals for the Eighth Circuit, in a suit brought by the Pharmaceutical Care Management Association, a national trade association representing PBMs, struck down a similar law in Iowa. The Iowa law, like Governor Cuomo's proposal, established generic drug pricing standards and required certain disclosures of drug pricing to Iowa's insurance commissioner. The Court of Appeals held the Iowa law explicitly and implicitly affected employee benefit plans covered by ERISA, which is impermissible. Significantly, the Court also held the Iowa law's requirement that PBMs disclose the economic basis for a plan's coverage of prescription drug benefits improperly "intrudes upon a matter central to plan administration and interferes with nationally uniform plan administration" in violation of ERISA. See Pharm. Care Mgmt. Ass'n v. Gerhart, 2017 U.S. App. LEXIS 476 (8th Cir. Jan. 11, 2017). It is uncertain how this ruling may impact the proposed New York reforms.

It appears any curbing of the "sky-rocketing" drug prices in New York is still a long way off, and may be subject to further delays caused by legal challenges by PBMs.

If you have questions or require further assistance regarding the information contained in this Legal Alert and the impact on your organization, please contact Brad M. Gallagher at, or Linda J. Clark, Chair of the Barclay Damon Health Care Controversies Practice Area at


Click here to sign up for alerts, blog posts, and firm news.


Sign up to receive our latest news via email

Practice Areas

Featured Industries

New & Emerging Industry Practice Areas


View our Privacy Policy

Featured Media


NYS Office of Renewable Energy Siting Proposes New Rules Implementing the Major Renewable Energy Development Program


Strict New Criteria for Community Medicaid Program Takes Effect October 1


FERC Formalizes Its Practice That States Have a Full Year to Act on Section 401 Certification Requests for Natural Gas Act Infrastructure Projects


Have You Received an "Urgent Notice" About Your Trademark?


COVID-19: Anticipated RESTAURANTS Act of 2020 Will Establish a $120 Billion Fund for Assistance


Post-ARRA COBRA Litigation May Signal COBRA Lawsuits to Come

This site uses cookies to give you the best experience possible on our site and in some cases direct advertisements to you based upon your use of our site.

By clicking [I agree], you are agreeing to our use of cookies. For information on what cookies we use and how to manage our use of cookies, please visit our Privacy Statement.

I AgreeOpt-Out